Amgen has disclosed a "material" cybersecurity incident in which attackers accessed the biopharma giant's cloud storage environments hosted by external service providers, stealing patient health information and proprietary company data. According to a securities filing, Amgen has confirmed the theft through its investigation. While the company reported no impact to products, manufacturing, financial reporting, or patient delivery, its investigation into the full scope of compromised records is ongoing. Amgen plans to notify affected patients.

The incident continues a wave of attacks against biopharma companies holding both high-value IP and sensitive patient data. Novo Nordisk was recently hit by a breach involving clinical trial participant data, with two extortion groups demanding multi-million-dollar ransoms — one, TheUSERS007, claimed to have used an adaptive AI engine called Venomware. Novartis faced a 2022 breach involving DNA and RNA drug technology data. The pattern points to two structural challenges: biopharma clouds concentrate uniquely valuable data at attackers' preferred entry point, and the rise of AI-assisted intrusion tooling is compressing the time from initial access to meaningful exfiltration. Regulators and investors are increasingly treating these events as material, which raises the bar on both detection speed and disclosure accuracy.

Cloud-hosted biopharma platforms need visibility that continuously monitors data access, API activity, and egress patterns, plus full-fidelity evidence retained long enough to answer scope questions weeks after the fact. When investigators can query a single indexed record of exactly what happened, materiality assessments and patient notifications can be made with specifics rather than placeholders. Platforms like NIKSUN give biopharma security teams the ability to detect cloud intrusions as they unfold and reconstruct scope quickly enough to meet SEC disclosure obligations and patient notification requirements. Read more about this story on our LinkedIn page